Freeline Therapeutics (FRLN)
NASDAQ: FRLN
· Real-Time Price · USD
6.49
0.01 (0.15%)
At close: Feb 16, 2024, 9:37 PM
Freeline Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -49.93M | -52.74M | -61.07M | -88.97M | -100.67M | -116.66M | -132.18M | -140.39M | -143.77M | -137.87M | -114.56M |
Depreciation & Amortization | 1.45M | 1.47M | 1.52M | 1.74M | 2.04M | 2.22M | 2.36M | 2.39M | 2.36M | 2.24M | 1.99M |
Stock-Based Compensation | 3.98M | 4.29M | 4.67M | 5.08M | 5.89M | 7.87M | 9.55M | 10.72M | 11.24M | 11.32M | 8.42M |
Other Working Capital | 2.13M | 2.75M | 6.94M | 3.62M | 17.24M | 18.68M | 16.21M | 22.54M | 7.42M | 2.51M | -4.24M |
Other Non-Cash Items | -22.46M | -27.77M | -25.33M | -4.98M | -4.92M | 371K | 216K | 148K | 78K | 79K | 13.12M |
Deferred Income Tax | -156K | -156K | -156K | -156K | 35K | 35K | 35K | -171K | -364K | -364K | -13.4M |
Change in Working Capital | 2.87M | 4.16M | 10.29M | 9.07M | 21.97M | 22.98M | 20.1M | 19.74M | 6.95M | -7.21M | -6.8M |
Operating Cash Flow | -64.24M | -70.74M | -70.08M | -78.22M | -75.66M | -83.18M | -99.92M | -107.56M | -123.5M | -131.8M | -111.23M |
Capital Expenditures | -4.55M | -6.72M | -6.88M | -7.01M | -3.75M | -2.55M | -2.52M | -4.27M | -5.37M | -4.62M | -4.52M |
Cash Acquisitions | 24.15M | 24.2M | 24.2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 112.43K | 66.03K | n/a | n/a | n/a | n/a | n/a | n/a | 126K | 126K | 411K |
Investing Cash Flow | 19.71M | 17.54M | 17.32M | -7.01M | -3.75M | -2.55M | -2.52M | -4.27M | -5.25M | -4.5M | -4.11M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 251.27K | 53.75K | 2.14M | 27.39M | 26.21M | 26.33M | 24.26M | -983.84K | 260.16K | 174.87M | 241.44M |
Financial Cash Flow | 67.36K | 25.18K | 2.19M | 27.52M | 26.35M | 26.35M | 24.26M | -984K | 260K | 174.87M | 241.44M |
Net Cash Flow | -37.91M | -52.79M | -59.37M | -70.46M | -70.75M | -74.87M | -82.73M | -112.51M | -114.46M | 58.75M | 143.94M |
Free Cash Flow | -68.79M | -77.46M | -76.96M | -85.24M | -79.42M | -85.73M | -102.44M | -111.83M | -128.87M | -136.43M | -115.75M |